Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study
{{output}}
Background: In the EMBRACE study, eribulin (ERI) monotherapy improved the overall survival (OS) of patients with HER2-negative advanced breast cancer (HER2-negative ABC). A post hoc analysis identified the baseline absolute lymph... ...
